Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
17 18 Next >
Cancer-Focused Imago BioSciences Shares Soar After Merck Deal
Via Benzinga
Expert Ratings for Seagen
Via Benzinga
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 15, 2022 – USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech... 
Via FinancialNewsMedia
Topics Death
Exposures Death
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen. 
Via Investor's Business Daily
Seagen Inc. (SGEN) Q3 2022 Earnings Call Transcript
SGEN earnings call for the period ending September 30, 2022. 
Via The Motley Fool
What 8 Analyst Ratings Have To Say About Seagen
Within the last quarter, Seagen (NASDAQ:SGEN) has observed the following analyst ratings: 
Via Benzinga
With Meaningful Upside, This Cancer Stock Earns Analyst Upgrade
Via Benzinga
Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
From Seagen Inc.
Via Business Wire
Seagen Appoints Sandra M. Swain, M.D., to Board of Directors
From Seagen Inc.
Via Business Wire
Seagen Names David R. Epstein as Chief Executive Officer and Director
From Seagen Inc.
Via Business Wire
Seattle Genetics's Return On Capital Employed Insights
Benzinga Pro data, Seattle Genetics (NASDAQ:SGEN) reported Q3 sales of $510.30 million. Earnings fell to a loss of $190.82 million, resulting in a 41.53% decrease from last quarter. 
Via Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
Honeywell International, Seagen, New York Community Bancorp And This Transportation Company Featured On CNBC's Final Trade
On CNBC’s “Halftime Report Final Trades,” Joseph Terranova of Virtus Investment Partners recommended buying shares of Seagen Inc. (NASDAQ: SGEN). 
Via Benzinga
Seagen Reports Third Quarter 2022 Financial Results
From Seagen Inc.
Via Business Wire
Earnings Scheduled For October 27, 2022
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million. 
Via Benzinga
What 9 Analyst Ratings Have To Say About Seagen
Over the past 3 months, 9 analysts have published their opinion on Seagen (NASDAQ:SGEN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's... 
Via Benzinga
A Bearish Sign Appears On Seagen's Chart
If history is any guide, there may be trouble ahead for shares of Seagen (NASDAQ:SGEN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock. 
Via Benzinga
Morgan Stanley Maintains Overweight Rating for Seagen: Here's What You Need To Know
Morgan Stanley has decided to maintain its Overweight rating of Seagen (NASDAQ:SGEN) and lower its price target from $181.00 to $170.00. Shares of Seagen are trading up 0.36% over the last 24 hours, at... 
Via Benzinga
Is Seagen Stock a Buy Now?
It's growing faster than competitors, but headwinds might soon bog it down. 
Via The Motley Fool
BMO Capital Upgrades Seagen: Here's What You Need To Know
BMO Capital upgraded its rating of Seagen (NASDAQ:SGEN) to Outperform with a price target of $178.00, changing its price target from $177.00 to $178.00. Shares of Seagen are trading up 2.5% over the... 
Via Benzinga
Biohaven Ltd. Surges 7.6%: Is This An Indication Of Further Gains?
Biohaven Ltd. shares ended the last trading session 7.6% higher at $13.18. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Upgrades 
Via Benzinga
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
Palm Beach, FL – October 6, 2022 – FinancialNewsMedia.com News Commentary – The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing... 
Via FinancialNewsMedia
Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2022 Financial Results on October 27, 2022
From Seagen Inc.
Via Business Wire
Week In Review: YishengBio To List On NASDAQ Via SPAC Merger At An $834 Million Value
Beijing YishengBio will merge with a SPAC vehicle, Summit Healthcare Acquisition, to list on the NASDAQ Exchange at a pre-money equity value of $834 million. The merger is expected to provide up to... 
Via Talk Markets
'Right Now, You've Still Got To Avoid The Stock,' Jim Cramer Says About This Aerospace Company
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Sherwin-Williams Co (NYSE: SHW) might go lower as the PE (price-to-earnings) multiple is still "way too high" on the stock. 
Via Benzinga
Joe Terranova Is Buying This Stock: Wednesday's CNBC 'Fast Money' Final Trades
CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned. The information is collected and refined... 
Via Benzinga
Seagen, Zai Lab Ink Regional Strategic Licensing Agreement For Cervical Cancer Treatment
Via Benzinga
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
From Seagen Inc.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.